Genetic determinants of susceptibility to osteoporosis

Omar Al Bagha, Stuart H. Ralston

Research output: Contribution to journalReview article

39 Citations (Scopus)

Abstract

Osteoporosis has a strong genetic component, and clinical studies have shown that heritable factors play a key role in regulating bone mineral density, ultrasound properties of bone, skeletal geometry, and bone turnover and contribute to the pathogenesis of osteoporotic fracture. In most cases, osteoporosis is caused by the combined effects of several different genes and their interaction with environmental influences, but it can occasionally occur as the result of mutations in a single gene. Genes that have been implicated in the regulation of bone mass in humans include the genes encoding lipoprotein receptor-related protein 5, sclerostin, transforming growth factor beta-1, collagen Iα1, vitamin D receptor, tumor necrosis factor receptor 2, and the estrogen receptor alpha. From a clinical standpoint, advances in knowledge about the genetic basis of osteoporosis are important because they offer the prospect of developing genetic markers for the assessment of fracture risk and the opportunity to identify molecules that will be used as targets for the design of new drugs for the prevention and treatment of bone disease.

Original languageEnglish
Pages (from-to)65-81
Number of pages17
JournalEndocrinology and Metabolism Clinics of North America
Volume32
Issue number1
DOIs
Publication statusPublished - Feb 2003
Externally publishedYes

Fingerprint

Genetic Predisposition to Disease
Osteoporosis
Genes
Low Density Lipoprotein Receptor-Related Protein-5
Receptors, Tumor Necrosis Factor, Type II
Bone and Bones
Calcitriol Receptors
Osteoporotic Fractures
Estrogen Receptor alpha
Bone Remodeling
Drug Design
Bone Diseases
Genetic Markers
Transforming Growth Factor beta
Bone Density
Collagen
Mutation

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Genetic determinants of susceptibility to osteoporosis. / Al Bagha, Omar; Ralston, Stuart H.

In: Endocrinology and Metabolism Clinics of North America, Vol. 32, No. 1, 02.2003, p. 65-81.

Research output: Contribution to journalReview article

@article{38ec1d65d46f4fe2a02018d0275ad769,
title = "Genetic determinants of susceptibility to osteoporosis",
abstract = "Osteoporosis has a strong genetic component, and clinical studies have shown that heritable factors play a key role in regulating bone mineral density, ultrasound properties of bone, skeletal geometry, and bone turnover and contribute to the pathogenesis of osteoporotic fracture. In most cases, osteoporosis is caused by the combined effects of several different genes and their interaction with environmental influences, but it can occasionally occur as the result of mutations in a single gene. Genes that have been implicated in the regulation of bone mass in humans include the genes encoding lipoprotein receptor-related protein 5, sclerostin, transforming growth factor beta-1, collagen Iα1, vitamin D receptor, tumor necrosis factor receptor 2, and the estrogen receptor alpha. From a clinical standpoint, advances in knowledge about the genetic basis of osteoporosis are important because they offer the prospect of developing genetic markers for the assessment of fracture risk and the opportunity to identify molecules that will be used as targets for the design of new drugs for the prevention and treatment of bone disease.",
author = "{Al Bagha}, Omar and Ralston, {Stuart H.}",
year = "2003",
month = "2",
doi = "10.1016/S0889-8529(02)00059-2",
language = "English",
volume = "32",
pages = "65--81",
journal = "Endocrinology and Metabolism Clinics of North America",
issn = "0889-8529",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Genetic determinants of susceptibility to osteoporosis

AU - Al Bagha, Omar

AU - Ralston, Stuart H.

PY - 2003/2

Y1 - 2003/2

N2 - Osteoporosis has a strong genetic component, and clinical studies have shown that heritable factors play a key role in regulating bone mineral density, ultrasound properties of bone, skeletal geometry, and bone turnover and contribute to the pathogenesis of osteoporotic fracture. In most cases, osteoporosis is caused by the combined effects of several different genes and their interaction with environmental influences, but it can occasionally occur as the result of mutations in a single gene. Genes that have been implicated in the regulation of bone mass in humans include the genes encoding lipoprotein receptor-related protein 5, sclerostin, transforming growth factor beta-1, collagen Iα1, vitamin D receptor, tumor necrosis factor receptor 2, and the estrogen receptor alpha. From a clinical standpoint, advances in knowledge about the genetic basis of osteoporosis are important because they offer the prospect of developing genetic markers for the assessment of fracture risk and the opportunity to identify molecules that will be used as targets for the design of new drugs for the prevention and treatment of bone disease.

AB - Osteoporosis has a strong genetic component, and clinical studies have shown that heritable factors play a key role in regulating bone mineral density, ultrasound properties of bone, skeletal geometry, and bone turnover and contribute to the pathogenesis of osteoporotic fracture. In most cases, osteoporosis is caused by the combined effects of several different genes and their interaction with environmental influences, but it can occasionally occur as the result of mutations in a single gene. Genes that have been implicated in the regulation of bone mass in humans include the genes encoding lipoprotein receptor-related protein 5, sclerostin, transforming growth factor beta-1, collagen Iα1, vitamin D receptor, tumor necrosis factor receptor 2, and the estrogen receptor alpha. From a clinical standpoint, advances in knowledge about the genetic basis of osteoporosis are important because they offer the prospect of developing genetic markers for the assessment of fracture risk and the opportunity to identify molecules that will be used as targets for the design of new drugs for the prevention and treatment of bone disease.

UR - http://www.scopus.com/inward/record.url?scp=0037299450&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037299450&partnerID=8YFLogxK

U2 - 10.1016/S0889-8529(02)00059-2

DO - 10.1016/S0889-8529(02)00059-2

M3 - Review article

C2 - 12699293

AN - SCOPUS:0037299450

VL - 32

SP - 65

EP - 81

JO - Endocrinology and Metabolism Clinics of North America

JF - Endocrinology and Metabolism Clinics of North America

SN - 0889-8529

IS - 1

ER -